1.	Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
2.	Anal Dysplasia Study of Men Who Have Sex With Men Living With HIV Phase: Phase IV Type: Diagnostic, Health services research, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 23592103, NCT01663558
3.	Radiation Therapy Plus Fluorouracil With or Without Additional Chemotherapy in Treating Patients with Primary Anal Cancer. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase III Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: NCRI-ACT-II, EU-20056, UKCCCR-ACT-II, ISRCTN26715889, NCT00025090
4.	Study Comparing Isolated Pelvic Perfusion With TNF-a 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer Phase: Phase III Type: Treatment Status: Active Age: 18 to 76 Sponsor: Other Protocol IDs: PIP2, CSET 1443, NCT00949039
5.	Infrared Coagulator Ablation or Observation in Preventing Anal Cancer in HIV-Positive Patients With Anal Neoplasia Phase: Phase III Type: Prevention, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: CDR0000681457, U01CA121947, AMC-076, NCT01164722
6.	Prevention of Oxaliplatin-induced Neuropathic Pain by a Specific Diet Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 to 70 Sponsor: Other Protocol IDs: CHU-0137, 2011-A00911-40, NCT01775449
7.	Probiotic LGG for Prevention of Side Effects in Patients Undergoing Chemoradiation for Gastrointestinal Cancer Phase: Phase III Type: Supportive care, Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: 12-X387, NCT01790035
8.	A Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: BBI608-201, NCT01325441
9.	Immune Therapy of HPV-induced Cancers Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: VicOryx, NCT01462838
10.	Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 55 Sponsor: Pharmaceutical / Industry Protocol IDs: AP611074.CT3, 2011-003760-80, NCT01532102
11.	Radiochemotherapy With Panitumumab in the Localised Epidermoid Carcinoma of the Anus Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FFCD 0904, NCT01581840
12.	A Phase I/II Evaluation of ADXS11-001, Mitomycin, 5-fluorouracil (5-FU) and IMRT for Anal Cancer Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: BrUOG 276, NCT01671488
13.	Cell Therapy of Cancer With Allogeneic Blood Lymphocytes Activated With Recombinant Interleukin-2 (rIL-2) for Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: Under 70 Sponsor: Other Protocol IDs: 271296-HMO-CTIL, NCT00149006
14.	Cetuximab, Cisplatin, Fluorouracil, and Radiation Therapy in Treating Patients With Stage I, Stage II, or Stage III Anal Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: CDR0000470269, ECOG-E3205, E3205, NCT00316888
15.	Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers Phase: Phase II Type: Treatment Status: Active Age: 20 to 80 Sponsor: Other Protocol IDs: C-206, UMIN000000961, NCT00594529
16.	External-Beam Radiation Therapy With or Without Indinavir and Ritonavir in Treating Patients With Brain Metastases. Note: The information about this trial has not been updated by the sponsor/principal investigator/lead organization. Cancer.gov cannot verify the accuracy of the information. Phase: Phase II Type: Treatment Status: Active Age: Not specified Sponsor: Other Protocol IDs: IOSI-RO0402, RO0402, NCT00637637
17.	A Phase II Study to Assess Acute Toxicity and Quality of Life of Patients With Carcinoma of the Anal Canal Receiving Chemotherapy and Radiation Using Helical Tomotherapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GI-24329, NCT00754078
18.	Study of Advanced Bulky Malignancies With Spatially Fractioned Radiation Therapy Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: GRID, NCT00765570
19.	Activated Allogeneic Lymphocytes for Induction Graft Versus Tumor Effect in Metastatic Solid Tumors Phase: Phase II Type: Treatment Status: Active Age: 12 to 70 Sponsor: Other Protocol IDs: 0457-08-HMO-CTIL, NCT00855452
20.	Vectibix for the Treatment of Anal Cancer Phase: Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: GEMCAD-0902, NCT01285778
21.	Alkagin Paste in the Prevention of Radiation Dermatitis Phase: Phase II Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: 11-052, NCT01408407
22.	A Phase II Study of Lymphodepletion Followed by Autologous Tumor-Infiltrating Lymphocytes and High-Dose Adesleukin for Human Papillomavirus-Associated Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: 120116, 12-C-0116, NCT01585428
23.	[F-18] Fluorothymidine PET/CT Imaging for Pelvic Cancers Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 201204712, R01CA169336, NCT01717391
24.	Oral Rigosertib for Squamous Cell Carinoma Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Onconova 09-09, COMIRB 13-0116, NCT01807546
25.	Sunitinib and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-2012-03112, 050909, U01CA132194, CINJ-050801, 050801, 0220080281, NCT00813423